Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference
16 févr. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
10 févr. 2021 22h49 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
10 févr. 2021 16h01 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event
14 janv. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering
07 janv. 2021 09h40 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
21 déc. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
23 nov. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
U.S. Phase 1 trial patient enrollment to begin in the first half of 2021China Phase 1 trial enrollment ongoingKey regulatory milestone achieved to enable further study of product candidate for...
Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
12 nov. 2020 16h05 HE
|
Onconova Therapeutics, Inc.
ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumorsInvestigator-initiated study advances with combination of oral rigosertib and nivolumab in K-RAS...
Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020
05 nov. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event
13 oct. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...